Clinical Trial Update: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and antitumor activity of BGB-3245 in participants with advanced solid tumors and B-Raf mutation-related tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BGB-3245

Snippet

Sponsor: MapKure, LLC | Conditions: Solid Tumor, B-Raf Mutation-Related Tumors | Phase 1 | Status: TERMINATED